

(h) BAFF-R-expressing L
cell clone D2C

Parental L cells




FIG. 1A




FIG. 1B




Figure 1 consists of two schematic diagrams, (a) and (b), representing different microstructures. Diagram (a) shows a circular unit cell with a central circular hole of radius r and a surrounding ring of radius R . Diagram (b) shows a rectangular unit cell with a central rectangular hole of width w and a surrounding ring of width W .




FIG. 1D




FIG. 1E




FIG. 2A




FIG. 2B




FIG. 2C

9/61




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5A

15/61

Rituximab Resistant Jeko-1 CD20 KO




FIG. 5B

16/61




FIG. 5C




FIG. 6A




FIG. 6B

19/61




FIG. 6C




FIG. 7A

Hybridoma clones screened by ELISA for antibody production

<i>Clone</i>	<i>(h)BAFF-R-expressing cells (OD 450 nm)</i>	<i>Parental L cell (OD 450 nm)</i>
C53	0.552	0.095
C55	1.067	0.102
C67	0.615	0.093
C90	0.645	0.116
C39	0.137	0.091

FIG. 7B




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14

29/61




FIG. 15




FIG. 16A




FIG. 16B

32/61




FIG. 16C

33/61




FIG. 17A

34/61




FIG. 17B




FIG. 18

36/61




FIG. 19A

37/61




FIG. 19B

38/61

BAFFR antibody binding affinity





FIG. 20A



H90 candidates/PBMC cytotoxicity

FIG. 20B




FIG. 21A




FIG. 21B

42/61




FIG. 22A




FIG. 22B

44/61





FIG. 23

45/61



Days after tumor challenge/ Days after CAR-T treatment

FIG. 24

CAR Construction
Schematic Structure

46/61



FIG. 25A

47/61

CAR-T cell production schedule




FIG. 25B

H90 CAR-T CTL assay




FIG. 26

H90 CAR-T cell proliferation
in vitro study




FIG. 27




FIG. 28A

51/61





FIG. 28B

Cytotoxic T Lymphocyte Assay

FIG. 29



Initial *in vivo* CAR-T study:
5M CAR-T; 2x treatment




FIG. 30A




FIG. 30B

JeKo-1 model, H55 CAR-T *in vivo* study




FIG. 31




FIG. 32A




FIG. 32B




FIG. 32C




FIG. 33A




FIG. 33B

60/61




FIG. 33C




FIG. 34